Novo Nordisk Pays $19M To Settle Prandin Antitrust Action
Novo Nordisk A/S has agreed to pay $19 million to settle a putative class action in Michigan federal court accusing it of attempting to monopolize the market for popular diabetes treatment...To view the full article, register now.
Already a subscriber? Click here to view full article